July 14, 2024: Ozempic Lawsuit Intensifies with New Studies Linking Drug to Vision Loss The Ozempic blindness and vision loss lawsuit is full steam ahead following the July 2024 study indicating huge increases in the risk of NAION for users of semaglutide
The clinical evidence base for GLP-1 therapy keeps expanding into new indication categories cardiovascular risk reduction, potential Alzheimer's benefit, heart failure management, sleep apnea, and kidney disease protection are all active investigation areas
Beyond heart health, GLP-1 agonists have also been shown to help the kidneys in people with type 2 diabetes and kidney disease
Based on SURMOUNT-1 data analysis, tirzepatide decreased the 10-year estimated risk of ASCVD for obese or overweight patients
Full author disclosures are available in the published study.
Glucagon-like peptide-1 receptor agonists and thyroid cancer risk